We reported that histone H3 lysine (K) 4 methyltransferase, , serves as a potent tumor-suppressor in melanoma, which was identified via epigenome-focused RNA interference (RNAi) screen. -deficient tumors show substantial reprogramming of key metabolic pathways including glycolysis via reduction of H3K4me1 (Histone H3K4 mono-methylation)-marked active enhancers, conferring sensitivity to inhibitors of glycolysis and IGFR (Insulin Growth Factor Receptor) pathway.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632269 | PMC |
| http://dx.doi.org/10.1080/23723556.2021.1984827 | DOI Listing |
Publication Analysis
Top Keywords
deficiency confers
4
confers therapeutic
4
therapeutic vulnerability
4
vulnerability glycolytic
4
glycolytic inhibitors
4
inhibitors melanoma
4
melanoma reported
4
reported histone
4
histone lysine
4
lysine methyltransferase
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!